Pain relief in patients receiving periocular botulinum toxin A

Ophthalmic Plastic and Reconstructive Surgery

Volumn 24, Issue 2, 2008, Pages 113-116

  Harrison, Andrew R ^a,b   Erickson, Jonathan P ^a   Anderson, Jill S ^a   Lee, Michael S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MMC 493 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ANALGESIA; ARTICLE; BLEPHAROSPASM; CONTROLLED STUDY; DRUG EFFICACY; EYE PAIN; FEMALE; HEADACHE; HEMIFACIAL SPASM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; FEMALE; HEMIFACIAL SPASM; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN; PALLIATIVE CARE; PATIENT SATISFACTION; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 41349115971     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/IOP.0b013e31816386e1     Document Type: Article

References (52)

1. Harrison AR. Chemodenervation for facial dystonias and wrinkles. Curr Opin Ophthalmol 2003;14:1-5.
2. Scott AB. Pharmacological weakening of extraocular muscles. Invest Ophthalmol 1973;12:924-7.
3. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980;87:1044-9.
4. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985;103:347-50.
5. Shorr N, Seiff SR, Kopelman J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol 1985;99:542-6.
6. Dutton JJ, Buckley EG. Long-term results and complications of botulinum toxin in the treatment of blepharospasm. Ophthalmology 1988;95:1529-34.
7. Lingua RW. Sequelae of botulinum toxin injection. Am J Ophthalmol 1985;100:305-7.
8. Savino PJ, Sergott RC, Bosley TM, Schatz NJ. Hemifacial spasm treated with botulinum a toxin injection. Arch Ophthalmol 1985;103:1305-6.
9. Mauriello JA. Blepharospasm, Meige syndrome, and hemifacial spasm: Treatment with botulinum toxin Neurology 1985;35:1499-500.
10. Perman KI, Baylis HI, Rosenbaum AL, Kirschen DG. The use of botulinum toxin in the medical management of benign essential blepharospasm. Ophthalmology 1986;93:1-3.
11. Frueh BR, Musch DC. Treatment of facial spasm with botulinum toxin. Ophthalmology 1986;93:917-23.
12. Engstrom PF, Arnoult JB, Mazow ML, et al. Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophthalmology 1987;94:971-5.
13. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Movement Disorders 1987;2:237-54.
14. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: A double-blind, placebo-controlled study. Neurology 1987;37:616 -23.
15. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53:633-9.
16. Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 1996;41:51-65.
17. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004;20:981-90.
18. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005;31:414-22.
19. Carruthers A, Langtry JAA, Carruthers J, Robinson G. Improvement of tension-type headaches when treating wrinkles with botulinum toxin A injections. Headache J Head Face Pain 1999;39:662-5.
20. Johnstone SJ, Adler CH. Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm. Headache 1998;38:366-8.
21. Kunig G, Pogarell O, Oertel WH. Facial pain in a case of cranial dystonia: a case report. Cephalalgia 1998;18:709-11.
22. Galvez-Jimenez N, Lampuri C, Patino-Picirrillo R, et al. Dystonia and headaches: clinical features and response to botulinum toxin therapy. Adv Neurol 2004;94:321-8.
23. Krack P, Hornig C, Dorndorf W. Resolution of chronic tension headache after botulinum toxin treatment of idiopathic blepharospasm. Movement Disorders 1995;10:388.
24. McCann JD, Gauthier M, Morschbacher R, et al. A novel mechanism for benign essential blepharospasm. Ophthal Plast Reconstr Surg 1999;15:384-9.
25. Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001;91:195-9.
26. Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 2002;18:S142-6.
27. Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J Neurol Sci 2005;235:1-9.
28. Carruthers J, Carruthers A. Botox: beyond wrinkles. Clin Dermatol 2004;22:89-93.
29. Zwart JA, Bovim G, Sand T, Sjaastad O. Tension headache: botulinum toxin paralysis of temporal muscles. Headache 1994;34:458-62.
30. Rollnik JD, Tanneberger O, Schubert M, et al. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 200;40:300-5.
31. Schmitt WJ, Slowey E, Fravi N, et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001;41:658-64.
32. Padberg M, de Bruijn SFTM, de Haan RJ, Tavy DLJ. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Chephalalgia 2004;24:675-80.
33. Schulte-Mattler WJ, Krack P; BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004;109:110-4.
34. Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998;38:468-71.
35. Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg 2000;123:669-76.
36. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 2003;43:853-60.
37. Relja M, Telarovic S. Botulinum toxin in tension-type headache. J Neurol 2004;251(suppl 1):112-4.
38. Freitag FG. Preventative treatment for migraine and tension-type headaches do drugs having effects on muscle spasm and tone have a role? CNS Drugs 2003;17:373-81.
39. Polo KB, Jabbari B. Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin. Movement Disorders 1994;9:233-5.
40. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofacial pain syndrome. Pain 1994;59:65-9.
41. Filippi GM, Errico P, Santarelli R, et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngologica 1993;113:400-4.
42. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996;19:488-96.
43. Wiegand H, Wellhoner HH. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch Pharmacol 1977;298:235-8.
44. Wiegand H, Erdmann G, Wellhoner HH. 125I-labeled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976;292:161-5.
45. Humm AM, Pabst C, Lauterburg T, Burgunder JM. Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Exp Neurol 2000;161:361-72.
46. Purkiss JR, Welch MJ, Doward S, Foster KA. Capsaicin stimulates release of substance P from dorsal root ganglion neurons via two distinct mechanisms. Biochem Soc Trans 1997;25:542S.
47. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Japan J Ophthalmol 2000;44:106-9.
48. Sala C, Andreose JS, Fumagalli G, Lomo T. Calcitonin generelated peptide: possible role in formation and maintenance of neuromuscular junctions. J Neurosci 1995;15:520-8.
49. Cui M, Aoki KR. Botulinum toxin type a (BTX-a) reduces inflammatory pain in the rat formalin model (abstract). Cephalalgia 2000;20:414-20.
50. Silberstein SD, Gobel H, Jensen R, et al. Botulinum toxin type A in the proylactic treatment of chronic tension-type headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. Cephalgia 2006;7:790-800.
51. Mathew NT, Frishberg BM, Gawel M. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:293-307.
52. Glogau RG. Botulinum A neurotoxin for axillary hyperhydrosis. Dermatol Surg 1998;24:817-9.